This interpretation may also shed light on the problem of the “hepsin paradox” [27]: Although hepsin is overexpressed in the vast majority of prostate cancers and is thought to promote tumor progression, it is unexpectedly underexpressed in metastatic lesions. The gene discussed is HPN; the disease is neoplasm.